Precision Medicine in Prostate Cancer VL

Clinical Understanding of PARP Inhibitors in Prostate Cancer - Elena Castro, Wassim Abida, and Karen Knudson

Details
Elena Castro, Wassim Abida, and Karen Knudsen discuss multiple topics regarding the use of PARP inhibitors in prostate cancer treatments. The three debate PARP response data, the functions of PARP inhibitors, the importance of androgen deprivation in the use of PARP inhibitors, and genomic testing in prostate cancer. Biographies: Karen Knudsen, Ph.D., Director, National Cancer Institute (NCI), Sid...

Best of ASCO 2020 Prostate Cancer - Oliver Sartor

Details
Oliver Sartor joins Alicia Morgans to speak about several prostate cancer studies making an impact on the diagnosis of prostate cancer and the treatment paradigm for this disease. They highlight 68Ga-PSMA-11 for pelvic nodal metastasis detection prior to radical prostatectomy and pelvic Lymph node dissection and the CONDOR study on the impact of PSMA-targeted imaging with 18F-DCFPyL-PET/CT in men...

TheraP: 177Lu-PSMA617 Theranostic vs Cabazitaxel in Progressive Metastatic Castration Resistant Prostate Cancer (mCRPC) - Michael Hofman & Ian Davis

Details
Ian Davis, MBBS, Ph.D., FRACP, and Michael Hofman, MBBS, FRACP, discuss the TheraP trial with Alicia Morgans, MD, MPH, which was presented at the ASCO 2020 virtual meeting. This study showed that in men with docetaxel-treated metastatic castration-resistant prostate cancer (mCRPC), LuPSMA was more active than cabazitaxel. Drs. Hofman and Davis provide insights into how Lutetium-PSMA works mechanis...

PARP Inhibition in Castration-resistant Prostate Cancer - Daniel Petrylak

Details
Dr. Dan Petrylak joins Tom Keane to discuss PARP inhibition in castration-resistant prostate cancer. In this lecture, Dr. Petrylak discusses the germline DNA repair mutations involved in prostate cancer. This is a state of the art lecture establishing the rationale for the clinical trials evaluating PARP inhibitors in metastatic castration-resistant prostate cancer. Biographies: Daniel P. Petrylak...

PARP Inhibitors Changing the Standard of Care for Treatment of Metastatic Prostate Cancer (mCRPC) - The PROfound Study

Details
Oliver Sartor joins Alicia Morgans to highlight the recently published PROfound Trial. A phase III trial of Lynparza (olaparib) in men with metastatic castration-resistant prostate cancer (mCRPC) who have a homologous recombination repair gene mutation and have progressed on prior treatment with new hormonal agent treatments. The PROfound trial was published in the New England Journal of Medicine...

TheraP Trial Design Evaluating 177Lu‐PSMA‐617 Theranostic Treatment vs Cabazitaxel in Progressive Metastatic Castration‐Resistant Prostate Cancer - Michael Hofman

Details
Michael Hofman, from the Peter MacCallum Cancer Centre in Melbourne, Australia joins Charles Ryan to go "beyond the VISION Trial" discussing ongoing clinical trials with lutetium, for example, TheraP: a randomized phase 2 trial of 177Lu‐PSMA‐617 theranostic treatment vs cabazitaxel in progressive metastatic castration‐resistant prostate cancer (Clinical Trial Protocol ANZUP 1603) where results are...

Genetically Informed Treatment for Advanced and Metastatic Prostate Cancer - Alicia Morgans

Details
Alicia Morgans, Associate Professor of Medicine at Northwestern University, shares her thoughts on genetically informed treatment for advanced and metastatic prostate cancer. Germline and somatic testing can have implications for patients in terms of their therapeutics and the main mutations. Morgans discusses the important germline and somatic mutations as well as the current data from clinical t...

Targeted Molecular Therapies for Treatment of Advanced Prostate Cancer - Scott Tagawa

Details
Scott Tagawa joins Alicia Morgans in discussing his recent research focus on radiopharmaceuticals for the treatment of prostate cancer. Dr. Tagawa highlights his studies evaluating both beta-emitting particles and alpha targeted particle therapies. Biographies: Scott T. Tagawa, MD, Associate Professor of Clinical Medicine, Clinical Urology, Medical Director, Genitourinary Oncology Research Program...

Imaging and Flare Responses When Assessing Patients with Metastatic Castration-Resistant Prostate Cancer - Anwar Padhani

Details
Anwar Padhani discusses his presentation from the 2019 Advanced Prostate Cancer Consensus Conference (APCCC) on the flare phenomenon in advanced prostate cancer. Because of this phenomenon, clinicians have created workarounds. Dr. Padhani expands that there are multiple consequences of the workarounds, one being that they cause delays in the treatment schedule. Precision oncology trials require ra...

High Activity Pain Reduction and Low Toxicity with Lu177 PSMA617 Theranostics - Michael Hofman

Details
Professor Michael Hofman presents details of a phase II prospective study on lutetium-PSMA-617. This study used the diagnostic companion of gallium-PSMA-11 to select patients with a high PSMA expression that were suitable for lutetium-PSMA-607 therapy. This was a prospective study. It was a 30 patient study and the results of that initial cohort were published in Lancet Oncology. This was followed...